StreetInsider.com News Articles

Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

Fri, 21 Nov 2025 12:07:00 +0000

TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency within the Canadian Department of National Defence that provides extensive expertise, infrastructure, and scientific capabilities to support the development of medical

Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

Fri, 21 Nov 2025 12:07:00 +0000

Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

Fri, 21 Nov 2025 12:07:00 +0000

Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

Fri, 21 Nov 2025 12:07:00 +0000

Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

Fri, 21 Nov 2025 12:07:00 +0000

Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

Fri, 21 Nov 2025 12:07:00 +0000

Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

Fri, 21 Nov 2025 12:07:00 +0000

Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

Fri, 21 Nov 2025 12:07:00 +0000

Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

Fri, 21 Nov 2025 12:07:00 +0000

Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

Fri, 21 Nov 2025 12:07:00 +0000

Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

Fri, 21 Nov 2025 12:07:00 +0000

Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

Fri, 21 Nov 2025 12:07:00 +0000

Revive Therapeutics closes second tranche of private placement for $91,400

Fri, 19 Sep 2025 17:00:39 +0000

Revive Therapeutics Ltd. (OTCQB: RVVTF) (CSE: RVV) announced the completion of a second tranche of its private placement, issuing 4,352,381 units at $0.021 per unit for gross proceeds of $91,400.

Each unit consists of one common share and one warrant. The warrants allow holders to purchase additional common shares at $0.05 each within 36 months of the closing date.

The company stated it will use proceeds for working capital and to pay certain trade payables. All securities issued are subject to a hold period expiring January 19, 2026.

The Toronto-based life sciences company previously announced the private placement on September 5, 2025, according

Revive Therapeutics closes second tranche of private placement for $91,400

Fri, 19 Sep 2025 17:00:39 +0000

Revive Therapeutics Ltd. (OTCQB: RVVTF) (CSE: RVV) announced the completion of a second tranche of its private placement, issuing 4,352,381 units at $0.021 per unit for gross proceeds of $91,400.

Each unit consists of one common share and one warrant. The warrants allow holders to purchase additional common shares at $0.05 each within 36 months of the closing date.

The company stated it will use proceeds for working capital and to pay certain trade payables. All securities issued are subject to a hold period expiring January 19, 2026.

The Toronto-based life sciences company previously announced the private placement on September 5, 2025, according

Revive Therapeutics closes second tranche of private placement for $91,400

Fri, 19 Sep 2025 17:00:39 +0000

Revive Therapeutics Ltd. (OTCQB: RVVTF) (CSE: RVV) announced the completion of a second tranche of its private placement, issuing 4,352,381 units at $0.021 per unit for gross proceeds of $91,400.

Each unit consists of one common share and one warrant. The warrants allow holders to purchase additional common shares at $0.05 each within 36 months of the closing date.

The company stated it will use proceeds for working capital and to pay certain trade payables. All securities issued are subject to a hold period expiring January 19, 2026.

The Toronto-based life sciences company previously announced the private placement on September 5, 2025, according

Revive Therapeutics closes second tranche of private placement for $91,400

Fri, 19 Sep 2025 17:00:39 +0000

Revive Therapeutics Ltd. (OTCQB: RVVTF) (CSE: RVV) announced the completion of a second tranche of its private placement, issuing 4,352,381 units at $0.021 per unit for gross proceeds of $91,400.

Each unit consists of one common share and one warrant. The warrants allow holders to purchase additional common shares at $0.05 each within 36 months of the closing date.

The company stated it will use proceeds for working capital and to pay certain trade payables. All securities issued are subject to a hold period expiring January 19, 2026.

The Toronto-based life sciences company previously announced the private placement on September 5, 2025, according

Revive Therapeutics Announces Closing of Second Tranche of Private Placement

Fri, 19 Sep 2025 17:00:00 +0000

TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it has closed a second tranche of its previously announced private placement (see press release of September 5, 2025) by issuing 4,352,381 units, at a price of $0.021 per unit, for gross proceeds to Revive of $91,400.

Each unit is comprised of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder to acquire

Revive Therapeutics Announces Closing of Second Tranche of Private Placement

Fri, 19 Sep 2025 17:00:00 +0000

Each unit is comprised of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder to acquire

Revive Therapeutics Announces Closing of Second Tranche of Private Placement

Fri, 19 Sep 2025 17:00:00 +0000

Each unit is comprised of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder to acquire

Revive Therapeutics Announces Closing of Second Tranche of Private Placement

Fri, 19 Sep 2025 17:00:00 +0000

Each unit is comprised of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder to acquire

Revive Therapeutics Announces Closing of Second Tranche of Private Placement

Fri, 19 Sep 2025 17:00:00 +0000

Each unit is comprised of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder to acquire

Revive Therapeutics Announces Closing of Second Tranche of Private Placement

Fri, 19 Sep 2025 17:00:00 +0000

Each unit is comprised of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder to acquire

Revive Therapeutics Announces Closing of Second Tranche of Private Placement

Fri, 19 Sep 2025 17:00:00 +0000

Each unit is comprised of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder to acquire

Revive Therapeutics Announces Closing of Second Tranche of Private Placement

Fri, 19 Sep 2025 17:00:00 +0000

Each unit is comprised of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder to acquire

Revive Therapeutics extends private placement offering deadline

Fri, 05 Sep 2025 19:51:07 +0000

Revive Therapeutics Ltd. (OTCQB: RVVTF) (CSE: RVV) announced an extension of its private placement offering of up to 30,952,381 units at $0.021 per unit for gross proceeds of up to $650,000.

The Toronto-based life sciences company closed a first tranche in August 2025, issuing 2,900,000 units for gross proceeds of $60,900. The company may close an additional $589,000 worth of units under the extended offering.

Each unit consists of one common share and one warrant. The warrants allow holders to purchase one common share at $0.05 for 36 months following closing. The unit price was based on the 20-day volume-weighted average price